IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Shenzhen Dobot 02432.HK	Advanced hardware and software	18.8-20.8	200	4,202	2024/12/18	Data is not available	2024/12/23
Minieye Tec 02431.HK	Application Software	17-20.2	200	4,081	2024/12/20	2024/12/24	2024/12/27
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	2024/12/27	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	2024/12/27	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	2024/12/27	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Shenzhen Dobot
02432.HK

Advanced hardware and software

18.8-20.8

200

4,202

2024/12/18

Data is not available

2024/12/23

Minieye Tec
02431.HK

Application Software

17-20.2

200

4,081

2024/12/20

2024/12/24

2024/12/27

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

2024/12/27

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

2024/12/27

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

2024/12/27

2024/12/30

Summary

We are a leading Hong Kong-based company that markets and distributes branded healthcare products with product footprint across Greater China, Southeast Asia and other select countries. In 2019, we ranked fourth by revenue among brand operators that carry both OTC proprietary medicines and OTC proprietary Chinese medicines in Hong Kong, according to the Frost & Sullivan Report. Our portfolio includes a wide range of quality branded healthcare products divided into two product categories: (i) consumer healthcare, consisting of branded medicines, which are proprietary medicines primarily distributed over-the-counter, and health and wellness products; and (ii) proprietary Chinese medicines, consisting of OTC proprietary Chinese medicines and concentrated Chinese medicine granules, or CCMG, products. Professionalism has been at the core of our corporate culture and our reputation is upheld through our persistence in product safety, efficacy and quality. We pride ourselves as a brand incubator and manager, with a proven track record of introducing well-established overseas branded products to our local markets, as well as rejuvenating heritage household brands to stimulate market demand and broaden their market appeal. We operate a vertically integrated business encompassing brand management and marketing, sourcing and representation of third-party brand products, development and manufacturing of own brand products, and sales and distribution. ‧ Brand management and marketing: We manage a portfolio of well-established and trusted third-party brands and own brands and are committed to continually driving brand engagement and sales through our multi-channel marketing campaigns. We seek to use our market and consumer insights to devise more precise product positioning and brand management strategies to improve our product appeal and consumer interests, and drive our product development initiatives. ‧ Sourcing and representation of third-party brand products: A majority of our consumer healthcare products are sourced from overseas third-party brand owners. As at March 31, 2020, we carried 11 principal third-party brands, the majority of which were sourced from Europe, including consumer healthcare products imported from reputable European GMP-accredited, ISO-certified or SGS-certified manufacturers. We generally obtain exclusive distribution rights from the third-party brand owners with which we enter into distributorship or in-licensing agreements for the sale and distribution of the relevant products in selected geographic markets. ‧ Development and manufacture of own brand products: As at March 31, 2020, we owned nine principal brands of branded healthcare products. The majority of our own brand products are OTC proprietary medicines and OTC proprietary Chinese medicines with long established proprietary formulations based on ancient prescriptions, pharmacopeia prescriptions or customary Chinese prescriptions. Tailored to the characteristics of our own brand product portfolio, our product development efforts have been directed towards product line extensions, formulation variations and formulation refinements for targeted overseas markets and expansion into new markets. ‧ Sales and distribution: We adopt a hybrid of sales and distribution models tailored for different products and geographic markets. In Hong Kong, we sell our products both directly and indirectly (through our Hong Kong Distributor and our trading company customers) to major modern trade chain stores, registered pharmacies and drug stores, as well as corporate clients, hospitals and clinics, and end consumers (through online platforms). In addition, we sell CCMG products to more than 3,000 Chinese medicine practitioners (which represented over 40% of the total number of active Chinese medicine practitioners in Hong Kong in 2019, according to the Frost & Sullivan Report), and from time to time, to non-profit organizations. Outside of Hong Kong, we sell selected products to China, Macau, Taiwan, and select countries in Southeast Asia, Europe, North America and the Caribbean Islands, primarily through distributorship and wholesaling arrangements. Meanwhile, we also devote dedicated resources to fulfill relevant product registration requirements and to closely monitor the regulatory regimes to ensure that our existing products and new products continue to comply with relevant product registration and product license requirements. ‧ Quality management: We enforce stringent quality assurance and control covering a wide range of activities, including procurement, manufacturing, release of finished products, stability studies, and validation and qualification of equipment and facilities. Our quality assurance personnel are responsible for ensuring GMP compliance, whereas our quality control personnel are responsible for arranging or carrying out all necessary and relevant tests on raw materials, manufacturing process, work in progress and finished products. Source: JBM Healthcare (02161) Prospectus (IPO Date : 2021/01/26)
Listing Market	MAIN
Industry	Health Care Supplies
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Sum Kwong Yip, Derek (62.39%) Yunnan Baiyao Group Co., Ltd. (9.23%)
Directors	Sum Kwong Yip, Derek (Chairman and Non-Executive Director) Wong Yat Wai, Patrick (Chief Executive Officer and Executive Director) Cheng Celine Heung Kwan (Executive Director) Yeung Kwok Chun, Harry (Non-Executive Director) Yim Chun Leung (Non-Executive Director) Chan Kam Chiu, Simon (Independent Non-Executive Director) Lau Shut Lee, Tony (Independent Non-Executive Director) Luk Ting Lung, Alan (Independent Non-Executive Director)
Company Secretary	Yu Chun Kau
Principal Bankers	The HongKong and Shanghai Banking Corporation Limited Chong Hing Bank Limited Standard Chartered Bank (Hong Kong) Ltd.
Solicitors
Auditors	KPMG
Registered Office	Units 808-811, 8th Floor, C-Bons International Centre, 108 Wai Yip Street, Kwun Tong, Kowloon, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	http://www.jbmhealthcare.com.hk
Email Address	enquiry@jbmhealthcare.com.hk
Tel No	(852) 2267-2182
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates